NVS Novartis AG

+0.74  (1%)
Previous Close 85.11
Open 85.64
Price To book 2.88
Market Cap 201137965000
Shares 2,342,900,000
Volume 1,773,692
Short Ratio 1.38
Av. Daily Volume 1,539,037

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - data due 7th Joint ECTRIMS-ACTRIMS meeting October 25 - 28, 2017.
FDA Approval announced June 22, 2017.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Phase 2 pivotal primary analysis presented International Conference on Malignant Lymphoma (ICML) on June 14, 2017. Abstract released June 7, 2017. Regulatory filing due 4Q 2017.
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3 updated data at ASCO June 4, 2017.
Ribociclib + Letrozole - MONALEESA-2
Breast cancer
Regulatory filing accepted for review - noted September 13, 2017.
GP2013 - Biosimilar rituximab
Non-Hodgkin’s Lymphoma
Phase 3 trial to commence in 2017.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 enrollment commenced March 2017. Trial to be completed in 2020.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 2 pivotal trial dosing initiation announced December 30, 2016.
Ruxolitinib - REACH 1
Steroid-refractory acute GVHD (Graft versus host disease)
Priority review granted February 22, 2017. Approval announced May 26, 2017.
First-line use in patients with ALK+ metastatic NSCLC
Phase 2 complete. Regulatory filing due 2018.
Sickle Cell Disease Pain Crises (SCPC)
Phase 3 trial met primary endpoint - data presented August 27, 2017 showed a 77% reduction in lung cancer mortality.
ACZ885 (canakinumab) - CANTOS
CV risk reduction
Phase 3 data released March 22, 2017 - primary endpoints not met.
Acute heart failure
Phase 3 data released June 20, 2017 - primary and key secondary endpoints met.
RTH258 (brolucizumab)
Neovascular AMD
Phase 3 data due 2018.
Phase 3 data due 2019.
QAW039 (fevipiprant)
Phase 3 trial completion 4Q 2017.
Breast cancer - (pre-menopausal)
Phase 3 data due 2019.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3 trial completion 4Q 2017.
Breast cancer - (post-menopausal)
Phase 3 trial completion due 2018.
Entresto - PIONEER
In-hospital initiation vs. enalapril following ADHF (acute decompensated heart failure)
Phase 3 interim analysis due 2018. Filing 2019.
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
Phase 3 trial completion due 2019. Filing 2020.
Entresto - PARADISE
AMI (acute myocardial infarction)
Approval announced early - August 30, 2017.
Kymriah (CTL019)
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
Phase 3 positive data released. Regulatory discussions ongoing.
Secondary progressive multiple sclerosis
Phase 3 data due 2018.
AIN457 (Cosentyx)
Non-radiographic axial SpA
Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
Phase 2/3 ongoing. Expected completion 2023.
CNP 520
Alzheimer’s Disease
Priority review granted November 14, 2016. Approval announced April 28, 2017.
Rydapt (Midostaurin - PKC412)
Acute myeloid leukemia (AML)
Priority review granted November 1, 2016. Approval announced March 13, 2017.
HR+/HER2- advanced breast cancer
BLA filing 2017.
Rheumatoid Arthritis

Latest News

  1. An Update on Novartis’s Sandostatin, Afinitor, and Exjade
  2. How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?
  3. An Update on Novartis’s Tafinlar and Mekinist post 1H17
  4. Novartis Announces Positive Data on Urticaria Drug Xolair
  5. Kisqali Could Significantly Boost Novartis’s Revenue Growth
  6. How Did Novartis Perform in 1H17?
  7. How Is Novartis’s Lucentis Positioned after 1H17?
  8. What Analysts Recommend for Novartis in September 2017
  9. AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share
  10. How Much Does It Really Cost to Develop a Cancer Drug?
  11. Novartis Sees IBD RS Rating Rise To 72
  12. Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx
  13. 3 Things Amgen Inc.'s Management Just Said That You'll Want to Know
  14. Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA
  15. 5 Ways To Play The Biotech Bull Market
  16. 5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition
  17. Foreign Stock Roundup: HMC Agrees on $605M Takata Air Bag Settlement, Narasimhan to Head Novartis
  18. Novartis posts a win, Roche a flop in skin cancer trials
  19. Lilly takes on Pfizer, Novartis with new breast cancer drug data
  20. [$$] Investors Chronicle: Redrow, Oxford BioMedica, Halfords